Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344058 | 0.88 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL343558 | 0.85 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17077055 | 0.85 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL9899781 | 0.84 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL14711403 | 0.81 | OPRM1 (0.52) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL342760 | 0.81 | PDCD1 (0.44) | — | |
| SCHEMBL10318609 | 0.80 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL29222886 | 0.79 | OPRM1 (0.63) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL9915903 | 0.79 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL18176049 | 0.79 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648726-B1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9556133-B2 | Polycyclic LPA1 antagonist and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| CN-103596566-A | Polycyclic LPA1 antagonists and uses thereof | AMIRA PHARMACEUTICALS INC | 2014-02-19 | — | — | CN | disclosed |
| EP-2438048-B1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2648726-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130253023-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-26 | — | — | US | disclosed |
| US-8273780-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2012078805-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2438048-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | LPAR1, LPAR2, LPAR4 | OPRM1 2949/4885OPRD1 2754/4885OPRK1 2227/4885 |
| US-20130253023-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | LPAR1, LPAR2, LPAR4 | OPRM1 3180/4885OPRD1 2968/4885OPRK1 2471/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | OPRM1 912/4885OPRD1 1013/4885OPRK1 588/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | OPRM1 912/4885OPRD1 1013/4885OPRK1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.